Technology | Embolization devices | August 17, 2015

Merit Medical Receives FDA Clearance Expanding Indication for QuadraSphere Microspheres

Applications for embolic agent now include malignant hepatoma

Merit Medical, QuadraSphere Microspheres, FDA approval, expanding indication, hepatoma

Image courtesy of Merit Medical Systems Inc.


August 17, 2015 — Merit Medical Systems Inc. announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) expanding indication for QuadraSphere Microspheres to include the embolization of hepatoma. Malignant hepatoma, also known as hepatocellular carcinoma (HCC), is the sixth most common cancer and the third leading cause of cancer deaths worldwide. QuadraSphere Microspheres are precisely calibrated and designed to offer controlled, targeted embolization, treating HCC by stopping blood flow to the tumors

For more information: www.merit.com

Related Content

News | Embolization devices

October 16, 2017 — Medtronic announced the launch of the Concerto 3-D Detachable Coil System at the Cardiovascular and ...

Home October 16, 2017
Home
News | Embolization devices

February 24, 2016 — ArtVentive Medical Group Inc. announced enrollment in the ongoing ArtVentive EOS Endoluminal ...

Home February 24, 2016
Home
Technology | Embolization devices

January 14, 2016 — Penumbra Inc. announced the U.S. launch of its new POD Packing Coil, designed as a complementary ...

Home January 14, 2016
Home
News | Embolization devices

December 17, 2015 — ArtVentive Medical Group conducted its first animal study of its next generation of the ArtVentive ...

Home December 17, 2015
Home
Subscribe Now